Emicizumab for Routine Prophylaxis in Hemophilia A: Clinical and Laboratory Experience Webinar
Emicizumab, a bispecific antibody that mimics the function of FVIIIa by bridging FIXa and FX, changed the paradigm of hemophilia A treatment. In this presentation, clinical data are presented and laboratory issues discussed.
- Bleeding
- Emicizumab
- Hemophilia
- Mechanical Circulatory Support
- hemophilia therapy
- PFA
- Extended half life products